Denali Therapeutics, Inc. (DNLI)
19.45
+0.78
(+4.18%)
USD |
NASDAQ |
Oct 09, 16:00
19.46
+0.01
(+0.03%)
After-Hours: 20:00
Denali Therapeutics Cash from Operations (Quarterly) : -97.00M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -97.00M |
| March 31, 2026 | -131.20M |
| December 31, 2025 | -98.54M |
| September 30, 2025 | -107.30M |
| June 30, 2025 | -75.30M |
| March 31, 2025 | -131.47M |
| December 31, 2024 | -83.72M |
| September 30, 2024 | -59.14M |
| June 30, 2024 | -91.22M |
| March 31, 2024 | -113.62M |
| December 31, 2023 | -98.66M |
| September 30, 2023 | -87.36M |
| June 30, 2023 | -113.17M |
| March 31, 2023 | -58.80M |
| December 31, 2022 | -72.66M |
| September 30, 2022 | -57.05M |
| June 30, 2022 | -42.90M |
| March 31, 2022 | -72.11M |
| December 31, 2021 | -65.49M |
| September 30, 2021 | -41.43M |
| Date | Value |
|---|---|
| June 30, 2021 | -54.22M |
| March 31, 2021 | -50.24M |
| December 31, 2020 | 513.92M |
| September 30, 2020 | 0.086M |
| June 30, 2020 | -43.36M |
| March 31, 2020 | -54.49M |
| December 31, 2019 | -47.64M |
| September 30, 2019 | -30.44M |
| June 30, 2019 | -43.18M |
| March 31, 2019 | -30.32M |
| December 31, 2018 | 93.18M |
| September 30, 2018 | -34.82M |
| June 30, 2018 | -41.82M |
| March 31, 2018 | 33.58M |
| December 31, 2017 | -18.34M |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | -18.37M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -177.47M |
| Oncolytics Biotech, Inc. | -8.066M |
| Sangamo Therapeutics, Inc. | -19.28M |
| Sarepta Therapeutics, Inc. | 197.07M |
| Anixa Biosciences, Inc. | -1.77M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -104.08M |
| Cash from Financing (Quarterly) | 14.98M |
| Free Cash Flow | -466.26M |
| Free Cash Flow Per Share (Quarterly) | -0.6759 |
| Free Cash Flow to Equity (Quarterly) | -124.25M |
| Free Cash Flow to Firm (Quarterly) | -126.61M |
| Free Cash Flow Yield | -13.28% |